Zolinza
Term · Oncology and biomedicine · MLC-T-ONC-009493
A drug used to treat cutaneous T-cell lymphoma that came back, got worse, or did not get better during or after treatment with two systemic therapies. It is also being studied in the treatment of other types of cancer. Zolinza blocks certain enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase inhibitor. Also called SAHA, suberoylanilide hydroxamic acid, and vorinostat.
| Identifier | MLC-T-ONC-009493 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | SAHA; suberoylanilide hydroxamic acid; vorinostat |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-009493",
"term": "Zolinza",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat cutaneous T-cell lymphoma that came back, got worse, or did not get better during or after treatment with two systemic therapies. It is also being studied in the treatment of other types of cancer. Zolinza blocks certain enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase inhibitor. Also called SAHA, suberoylanilide hydroxamic acid, and vorinostat.",
"synonyms": [
"SAHA",
"suberoylanilide hydroxamic acid",
"vorinostat"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/zolinza/"
}
Record 17,692 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.